OBJECTIVES: Patient reported outcomes (PRO) are becoming useful tools for collecting and generating evidence for new medical products to show improvements in health-related quality of life (HRQoL). Chronic myeloid leukemia (CML) is now a chronic disease in which HRQoL is becoming important.  The objective of this study was to review, analyze, and understand trends in the PRO instruments used in patients with CML. METHODS: A systematic literature search for CML randomized controlled trials (RCTs) with PROs endpoints was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar, and Cochrane. Data was collected for the study size, interventions, year, PRO instrument, and results for PROs. Analysis  was conducted to identify trends in commonly used PRO instruments and results were categorized  as positive, neutral, or negative. RESULTS: Eight RCTs with a total of 3342 patients were identified. In these studies, there were eight different PROs instruments identified: FACT-Leu, SF-36, FSI, PSQI, MSAS-SF, FACT-BRM, EQ-5D, and MDASI-CML. The most commonly used instruments were FACT-Leu (used in 1336 patients) and FACT-BRM (used in 1199 patients). Five studies reported positive results with improvement in quality of life (QoL) symptoms versus comparator treatments. Two studies reported results highlighting significant deterioration in QoL versus patients with no cancer. One study reported QoL in various types of CML and showed significant deterioration in patients with chronic phase CML versus those with acute and blast phase CML. Studies also identified two QoL domains, depression and fatigue, which matter most for patients with CML. CONCLUSIONS: Patients with CML have significant deterioration in their QoL. PRO instruments such as FACT-Leu and FACT-BRM can aid in generating evidence to show which therapies improve patient QoL.